hotspot -WSS

hotspot

author：hotspot 2025-08-07 16:18:42 - browse：73772

Vertex Pharmaceuticals Inc. building — Craig F. Walker/The Boston Globe

Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease.

The results, presented at the American Diabetes Association conference in San Diego, bolstered experts’ hopes that the treatment could provide a functional cure for some patients. In 2021, Vertex announced dramatic results from the first man to receive the treatment, but researchers cautioned it was just one person, who had only been followed for 90 days.

“The data look as good as they could be,” said Jeanne Loring, a stem cell expert and professor emeritus at Scripps Research not involved in the work, in an email.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： STAT Boddities: What happens to the brain when we get scared?

entertainment

WSS

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Juul documents reveal insider tactics on political lobbying

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Amylyx ALS drug fails large clinical trial

Too many hospitalized Covid

focus

hotspot

explore

Sports medicine is finally prioritizing gender equality

Having children helps parents live longer, especially after age 80

George Santos makes 1st court appearance after pleading not guilty to 13 counts

IVF, abortion rights issues kick off Biden’s State of the Union

The cancer drug shortage isn’t new — and neither are the solutions

Sen. Paul opposes bill to ban Chinese biotechs

Cancer drug shortages should be causing more outrage

Websites selling Wegovy, Zepbound ingredients targeted by FDA

United colonoscopy coverage change 'may cost lives,' doctors say

CDC marks new Covid

leisure time

The drug industry has found itself all alone in Washington

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Amylyx ALS drug failure raises questions and concerns

Congress might make insulin pumps more accessible to the blind

CDC marks new Covid

Former medical device CEO who sold dummy, plastic parts convicted of fraud

entertainment

Wikipedia

focus

knowledge